会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • INHIBITION OF ALPHA SYNUCLEIN TOXICITY
    • 抑制ALPHA综合征毒性
    • WO2009021295A3
    • 2009-05-14
    • PCT/BE2008000062
    • 2008-08-07
    • UNIV LEUVEN KATHUNIV GRAZBAEKELANDT VEERLEBUETTNER SABRINAMADEO FRANKWINDERICKX JORIS
    • BAEKELANDT VEERLEBUETTNER SABRINAMADEO FRANKWINDERICKX JORIS
    • C07K16/40A61K38/00A61P25/16A61P25/28C12N15/113
    • A61K39/3955A61K31/713A61K38/005A61K2039/505C07K16/40C12N15/1137C12N2310/14
    • Present inventions demonstrates that alpha synculein toxicity such as a-synuclein mediated cell death, alpha synuclein induced reactive oxygen species (ROS) in a cell requires the proapoptotic endonuclease G and that the deletion of the endonuclease G or suppressing of the endonuclease G apoptotic pathway attenuates or counteracts such alpha synuclein toxicity. The present invention compositions and methods for inhibition of a-synuclein toxicity. The inhibiting a-synuclein toxicity can be used in methods of treatment of synucleinopathies, such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), pure autonomic failure (PAF), and multiple system atrophy (MSA) and the manufacture of medicaments for such treatment. In particular The subject matter provided in herein relates to a pharmaceutical compositions containing inhibitors of endonuclease G, and their use in the treatment of synucleinopathies, such as Parkinson's disease, dementia with Lewy bodies, pure autonomic failure, and multiple system atrophy and the manufacture of medicaments for such treatment. Furthermore the present invention relates to a method for the identification of compounds attenuating the synuclein toxicity, said method comprising evaluating the inhibitory action of said compound on the endonuclease G dependent apoptosis.
    • 本发明证明α-突触素毒性如α-突触核蛋白介导的细胞死亡,α突触核蛋白在细胞中诱导活性氧(ROS)需要促凋亡内切酶G,并且内切核酸酶G的缺失或内切核酸酶G凋亡通路的抑制减弱 或抵抗这种α突触核蛋白毒性。 本发明的组合物和抑制α-突触核蛋白毒性的方法。 抑制性α-突触核蛋白毒性可用于治疗突触核蛋白病,如帕金森病(PD),路易体痴呆(DLB),纯自主神经功能衰竭(PAF)和多系统萎缩(MSA) 药物用于治疗。 特别地,本文提供的主题涉及含有内切核酸酶G抑制剂的药物组合物及其在治疗突触核蛋白病(例如帕金森病,路易体痴呆,纯粹的自主神经衰竭和多系统萎缩)中的用途,以及制造 药物用于治疗。 此外,本发明涉及鉴定减毒突触核蛋白毒性的化合物的方法,所述方法包括评估所述化合物对核酸内切酶G依赖性凋亡的抑制作用。